Bone Marrow Transplantation News

A myeloablative fractionated busulfan regimen with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis appeared feasible for older patients with hematologic malignancies, according to results of a single-arm phase 2 study presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Nonmyeloablative conditioning in combination with post-transplant cyclophosphamide and thiotepa appeared feasible for patients with severe transfusion-dependent thalassemia undergoing bone marrow transplantation, according to results of a phase 1 study presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Individuals aged 65 years or older received potentially inappropriate medications after allogeneic hematopoietic stem cell transplantation as frequently as their younger counterparts aged 40 to 64 years, according to results of a study presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Duration of remission prior to post-transplant relapse, as well as survival after relapse, appeared to be strong independent predictors of whether pediatric patients with high-risk leukemia or myelodysplastic syndrome can receive a second allogeneic hematopoietic stem cell transplant, according to results of a retrospective study presented at TCT | Transplantation & Cellular Therapy Meetings.

Phenotype-guided dosing strategies can increase the proportion of patients with hematologic malignancies who achieve a therapeutic drug concentration of prophylactic voriconazole, according to results of two studies published in Clinical Pharmacology & Therapeutics.

ORLANDO — Targeted conditioning with anti-CD45 iodine apamistamab enabled older, heavily pretreated patients with relapsed or refractory acute myeloid leukemia to undergo hematopoietic stem cell transplantation with successful engraftment, according to preliminary results of the randomized phase 3 SIERRA trial presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Individualized dosing of rabbit anti-thymocyte globulin significantly improved CD4-positive T-cell recovery after allogeneic hematopoietic stem cell transplantation among children, according to results of the open-label phase 2 PARACHUTE study presented at TCT | Transplantation & Cellular Therapy Meetings.

Patterns of microbiota disruption, marked by loss of intestinal diversity and single taxa domination, appeared similar among a cohort of patients undergoing allogeneic hematopoietic stem cell transplantation across various centers and geographic areas, according to findings published in The New England Journal of Medicine.

ORLANDO — The novel antiviral agent letermovir appeared effective for primary cytomegalovirus prevention among haploidentical stem cell transplant recipients, according to results of a single-center chart review presented at TCT | Transplantation & Cellular Therapy Meetings.

The number of APPs continues to increase considerably in the U.S., with higher health care costs and physician shortages — particularly in rural areas lacking health care access — driving this increase.